CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of Kelley Boucher as the Company’s Senior Vice President (SVP), Chief Human Resources Officer (CHRO) and the promotion of Kevin Fitzgerald, Ph.D., as SVP, Chief Scientific Officer (CSO).
“We are thrilled to have Kelley join our executive team and look forward to working with her on building Alnylam for the future, including acquisition of top talent, development of our leaders, and maintaining our culture as we grow and scale,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “With Kevin’s promotion and new role as our CSO, we are sure to continue to innovate and fuel our R&D engine in a manner that sustains pipeline growth for many years to come.”
Kelley Boucher, SVP, CHRO
"It’s wonderful to join Alnylam at a time when the Company is reaping the benefits of its innovation and has transitioned to commercialization of its potentially life-changing medicines. This transition, along with the advancement of the Company’s robust and diverse pipeline, will be enabled by continued investment in global growth, scalability, and people development. I hope to help foster this growth by ensuring that we are an employer of choice and that we continue to cultivate an inclusive and diverse culture conducive to forward thinking and innovation,” said Ms. Boucher.
In this role, Ms. Boucher will help guide organizational design and development, talent management, team effectiveness, culture, change management, and strategic talent acquisition – all while ensuring that Alnylam culture and philosophy are scalable and permeate the Company’s 26 current offices across 18 countries around the world.
Ms. Boucher comes with over 15 years of human resources and talent acquisition/management experience in the biotech sector. Most recently, Ms. Boucher was the Vice President (VP) and Head of Global Human Resources for Abiomed, a medical device company. Prior to this, she was VP, Head of Human Resources for Corporate Divisions at Shire Pharmaceuticals where she spent 10 years holding multiple positions of increasing responsibility. Earlier in her career, Ms. Boucher was a Principal Consultant for Clockwork Consulting and held Human Resources roles at Syntonix Pharmaceuticals and Digitas. Kelley holds a Bachelor of Arts, Government Relations degree from Cornell University.
Kevin Fitzgerald, Ph.D., SVP, CSO
“It’s been a privilege to contribute to the growth of our rich pipeline and our Company’s evolution, having pioneered the translation of RNAi therapeutics from a Nobel Prize-winning discovery to a new class of medicines with the potential to transform the lives of thousands of underserved patients worldwide,” said Dr. Fitzgerald. “I am very excited to lead the discovery and development of the next wave of Alnylam’s RNAi therapeutics.”
In his role, Dr. Fitzgerald will be responsible for the strategic direction and oversight of Alnylam’s discovery engine. He has over 20 years of experience in the context of small molecule and oligonucleotide drug discovery. Dr. Fitzgerald’s tenure at Alnylam began in 2005 when he joined as an Associate Director of Research. He has headed the Research department since 2016. His achievements include leadership of Alnylam’s RNAi delivery efforts, resulting in two clinically validated modes of siRNA delivery, as well as the development of the Company’s comprehensive clinical pipeline. He is an inventor on over 50 patents that apply to the majority of Alnylam’s pipeline programs, and the author of over 40 manuscripts, including many in prestigious journals such as Nature, Cell, and The New England Journal of Medicine. Kevin has led or supported multiple programs from discovery through various stages of clinical development. Kevin received his Bachelor of Science in Genetics from Cornell University and his doctorate in Molecular Biology from Princeton University. He completed his post-doctoral fellowship at Harvard Medical School.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a new class of
innovative medicines with the potential to transform the lives of people
afflicted with rare genetic, cardio-metabolic, hepatic infectious, and
central nervous system/ocular diseases. Based on Nobel Prize-winning
science, RNAi therapeutics represent a powerful, clinically validated
approach for the treatment of diseases with high unmet need. ONPATTRO®
(patisiran) is the first-ever RNAi therapeutic approved by the U.S. FDA
for the treatment of the polyneuropathy of hereditary
transthyretin-mediated (hATTR) amyloidosis in adults and by the EMA for
the treatment of hATTR amyloidosis in adults with stage 1 or stage 2
polyneuropathy. Alnylam has a deep pipeline of investigational
medicines, including six product candidates in Phase 3 studies. Looking
forward, Alnylam will continue to execute on its "Alnylam 2020"
strategy of building a multi-product, commercial-stage biopharmaceutical
company with a sustainable pipeline of RNAi-based medicines to address
the needs of patients who have limited or inadequate treatment options.
Headquartered in Cambridge, MA, Alnylam employs over 1,200 people
worldwide. For more information about our people, science and pipeline,
please visit www.alnylam.com
and engage with us on Twitter at @Alnylam
or on LinkedIn.
